This video is part of a three-part series covering new literature that could influence clinical practice. In this video, I discuss whether beta-blocker use post-MI is beneficial for patients with HFpEF. Background about the mechanism of action and typical place in therapy leads into background studies leading to the current research. Finally, the REDUCE-AMI study is summarized with its major findings and discussion about the potential to influence practice. This video was created by Emma Carlberg, PharmD Candidate.

Did you enjoy this blog post? Subscribers are emailed new blog posts TWICE per week! In addition, you’ll get access to the free giveaways below. Over 6,000 healthcare professionals have subscribed for our FREE Giveaways. Why haven’t you?!

• 30 medication mistakes PDF
• 18+ Page Drug Interaction PDF
• 10 Commandments of Polypharmacy Webinar based on my experiences in clinical practice